Article Details
Retrieved on: 2021-06-16 11:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... upfront to co-develop and co-commercialise EOS-448 – an anti-TGIT monoclonal antibody (mAb) in phase 1 testing as a potential cancer treatment.
Article found on: www.pmlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here